AbbVie Overview

  • Status
  • Public

  • Employees
  • 57,000

Employees

  • Stock Symbol
  • ABBV

Stock Symbol

  • Investments
  • 45

  • Share Price
  • $295.03
  • (As of Friday Closing)

AbbVie General Information

Description

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.

Contact Information

Website
www.abbvie.com
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 1 North Waukegan Road
  • North Chicago, IL 60064
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
NYS
Vertical(s)
Corporate Office
  • 1 North Waukegan Road
  • North Chicago, IL 60064
  • United States

AbbVie Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AbbVie Stock Performance

As of 13-Nov-2026, AbbVie’s stock price is $295.03. Its current market cap is $521B with 1.77B shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$295.03 $294.45 $190.75 - $302.93 $521B 1.77B 4.79M $5.82

AbbVie Financials Summary

As of 30-Sep-2026, AbbVie has a trailing 12-month revenue of $66B.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 526,560,211 466,944,715 377,853,835 321,096,334
Revenue 66,014,000 61,160,000 56,334,000 54,318,000
EBITDA 23,160,000 17,363,000 14,262,000 16,632,000
Net Income 10,342,000 4,226,000 4,278,000 4,863,000
Total Assets 147,680,000 133,960,000 135,161,000 134,711,000
Total Debt 80,903,000 67,496,000 67,144,000 59,385,000
Public Fundamental Data provided by Morningstar, Inc. disclaimer

AbbVie Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore AbbVie‘s full profile, request access.

Request a free trial

AbbVie Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (wi
Drug Discovery
North Chicago, IL
57,000 As of 2025

Cambridge, MA
 

Foster City, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AbbVie Competitors (32)

One of AbbVie’s 32 competitors is Biogen, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Biogen Formerly VC-backed Cambridge, MA
Gilead Formerly VC-backed Foster City, CA
Lilly USA Corporation Indianapolis, IN
Amgen Formerly PE-Backed Thousand Oaks, CA
Roche Corporation Basel, Switzerland
You’re viewing 5 of 32 competitors. Get the full list »

AbbVie Patents

AbbVie Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026226780-A1 Anti-nectin-4 conditional il-15 immuno-cytokines Pending 23-Apr-2025
US-20260306664-A1 Prophylactic steroid regimen for recombinant adeno-associated viral vector therapies Pending 03-Apr-2025
WO-2026213546-A1 Prophylactic steroid regimen for recombinant adeno-associated viral vector therapies Pending 03-Apr-2025
WO-2026210399-A1 Amylin agonist for use in a method of treating obesity Pending 01-Apr-2025
JP-2026159374-A Triple-specific binding protein Pending 20-Mar-2025 C07K16/2851
To view AbbVie’s complete patent history, request access »

AbbVie Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AbbVie Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore AbbVie‘s full profile, request access.

Request a free trial

AbbVie Investments & Acquisitions (45)

AbbVie’s most recent deal was a Corporate Asset Purchase with Nxera Pharma (NXE0033744 in United Kingdom) for . The deal was made on 04-Nov-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Nxera Pharma (NXE0033744 in United Kingdom) 04-Nov-2026 Corporate Asset Purchase Buildings and Property
ADARx Pharmaceuticals 01-Oct-2026 PIPE Drug Discovery
Apogee Therapeutics 03-Sep-2026 Merger/Acquisition Biotechnology
West Pharmaceutical Services (Device Manufacturing Facility in Tempe, Arizona) 01-Jul-2026 Corporate Asset Purchase Buildings and Property
Kestrel Therapeutics 28-Apr-2026 Merger/Acquisition Drug Discovery
You’re viewing 5 of 45 investments and acquisitions. Get the full list »

AbbVie ESG

Risk Overview

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view AbbVie’s complete esg history, request access »

AbbVie Exits (6)

AbbVie’s most recent exit was on 09-Jun-2021 from Kojin TX. The exit was categorized as with 11 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Kojin TX 09-Jun-2021 Completed
  • 11 buyers
Lyndra Therapeutics 11-Feb-2019 Completed
  • 15 buyers
BioArctic 20-Sep-2016 Completed
  • 4 buyers
Reata Pharmaceuticals 26-May-2016 Completed
MIMETAS 22-Dec-2015 Grant Completed
  • 6 buyers
You’re viewing 5 of 6 exits. Get the full list »

AbbVie Affiliates

Subsidiaries (8)

Name Industry Location Year Founded
Apogee Therapeutics Waltham, MA 2022
DJS Antibodies Bicester, United Kingdom 2014
Abbott - AbbVie Multiple Employer Pension Plan Abbott Park City, IL 2013
AbbVie (Women's Drug Portfolio) Dublin, Ireland 2012
iSTAR Medical Wavre, Belgium 2010
You’re viewing 5 of 8 affiliates. Get the full list.  »

AbbVie FAQs

  • Where is AbbVie headquartered?

    AbbVie is headquartered in North Chicago, IL.

  • What is the size of AbbVie?

    AbbVie has 57,000 total employees.

  • What industry is AbbVie in?

    AbbVie’s primary industry is Drug Discovery.

  • Is AbbVie a private or public company?

    AbbVie is a Public company.

  • What is AbbVie’s stock symbol?

    The ticker symbol for AbbVie is ABBV.

  • What is the current stock price of AbbVie?

    As of 13-Nov-2026 the stock price of AbbVie is $295.03.

  • What is the current market cap of AbbVie?

    The current market capitalization of AbbVie is $521B.

  • What is AbbVie’s current revenue?

    The trailing twelve month revenue for AbbVie is $66B.

  • Who are AbbVie’s competitors?

    Biogen, Gilead, Lilly USA, Amgen, and Roche are some of the 32 competitors of AbbVie.

  • What is AbbVie’s annual earnings per share (EPS)?

    AbbVie’s EPS for 12 months was $5.82.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process